Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy-Reference-Cited by-同舟云学术

Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy

Published:2003-02 Issue:2 Volume:38 Page:200-207
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Imamura Hiroshi,Matsuyama Yutaka,Tanaka Eiji,Ohkubo Takao,Hasegawa Kiyoshi,Miyagawa Shinichi,Sugawara Yasuhiko,Minagawa Masami,Takayama Tadatoshi,Kawasaki Seiji,Makuuchi Masatoshi

Publisher

Elsevier BV

Subject

Hepatology

Reference37 articles.

1. Early hepatocellular carcinoma as an entity with a high rate of surgical cure;Takayama;Hepatology,1998

2. Recurrence of hepatocellular carcinoma after surgery;Yamamoto;Br J Surg,1996

3. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma;Tung-Ping Poon;Ann Surg,2000

4. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma;Imamura;Br J Surg,1999

5. Surgery for small liver cancers;Makuuchi;Semin Surg Oncol,1993

Cited by 1337 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

2. Tenofovir versus entecavir on the prognosis of hepatitis B virus-related hepatocellular carcinoma: a reconstructed individual patient data meta-analysis;Frontiers in Pharmacology;2024-08-22

3. Multi-transcriptomics analysis of microvascular invasion-related malignant cells and development of a machine learning-based prognostic model in hepatocellular carcinoma;Frontiers in Immunology;2024-08-08

4. Postoperative adjuvant immunotherapy and molecular targeted therapy for patients of hepatocellular carcinoma with portal vein tumor thrombus after hepatectomy: a propensity score matching study;Frontiers in Surgery;2024-08-07

5. Intraindividual comparison of prognostic imaging features of HCCs between MRIs with extracellular and hepatobiliary contrast agents;Liver International;2024-08-06